Detecting salivary host and microbiome RNA signature for aiding diagnosis of oral and throat cancer
Guruduth Banavar,Oyetunji Ogundijo,Cristina Julian,Ryan Toma,Francine Camacho,Pedro J Torres,Lan Hu,Tarun Chandra,Andrew Piscitello,Liz Kenny,Sarju Vasani,Martin Batstone,Nevenka Dimitrova,Momchilo Vuyisich,Salomon Amar,Chamindie Punyadeera
DOI: https://doi.org/10.1016/j.oraloncology.2023.106480
Abstract:Objective: Oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) can go undetected resulting in late detection and poor outcomes. We describe the development and validation of CancerDetect for Oral & Throat cancer™ (CDOT), to detect markers of OSCC and/or OPSCC within a high-risk population. Material and methods: We collected saliva samples from 1,175 individuals who were 50 years or older, or adults with a tobacco use history. 945 of those were used to train a classifier using machine learning methods, resulting in a salivary microbial and human metatranscriptomic signature. The classifier was then independently validated on the 230 remaining samples prospectively collected and unseen by the classifier, consisting of 20 OSCC (all stages), 76 OPSCC (all stages), and 134 negatives (including 14 pre-malignant). Results: On the validation cohort, the specificity of the CDOT test was 94 %, sensitivity was 90 % for participants with OSCC, and 84.2 % for participants with OPSCC. Similar classification results were observed among people in early stage (stages I & II) vs late stage (stages III & IV). Conclusions: CDOT is a non-invasive test that can be easily administered in dentist offices, primary care centres and specialised cancer clinics for early detection of OPSCC and OSCC. This test, having received FDA's breakthrough designation for accelerated review, has the potential to enable early diagnosis, saving lives and significantly reducing healthcare expenditure.